Back to top

Analyst Blog

Novo Nordisk (NVO - Analyst Report) recently submitted marketing applications to the European Medicines Agency (EMA) seeking approval for its type II diabetes candidate, IDegLira.

IDegLira is the combination product of insulin degludec, Tresiba and Victoza, the once-daily human GLP-1 analogue.

The application was based on data from the DUAL program, which consisted of two phase IIIa studies.

Patients treated with IDegLira achieved an average HbA1c reduction of 1.9% in both studies. HbA1c treatment target of 7% were achieved by 81% of the patients earlier treated with oral anti-diabetics and 60% of the patients previously treated with basal insulin.

The open-label DUAL I study, which enrolled 1,600 people, compared the efficacy and safety of IDegLira, Tresiba and Victoza in people with type II diabetes inadequately controlled with metformin with or without pioglitazone. DUAL I data was released in Aug 2012.

In Dec 2012, Novo Nordisk announced the completion of DUAL II, the second and final phase IIIa program for IDegLira. DUAL II demonstrated that patients can realize benefits from each of the components in the combination product and reconfirmed the competitive profiles of Tresiba and Victoza.

Novo Nordisk is working to make IDegLira available in a prefilled device.

Novo Nordisk has a strong presence in the diabetes care market. The company has one of the broadest diabetes portfolios in the industry. The Diabetes Care segment recorded growth of 15% in 2012 with sales coming in at DKK 60.9 billion. 2012 results were driven by strong revenues from NovoRapid, Levemir and Victoza. Victoza witnessed sales growth of 58% in 2012.

Novo Nordisk carries a Zacks Rank #3 (Hold). Currently, companies like Santarus, Inc. , Jazz Pharmaceuticals (JAZZ - Analyst Report) and Salix Pharmaceuticals Ltd. (SLXP - Analyst Report) look well positioned with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%